Page 7 - Sabcs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sabcs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sabcs Today - Breaking & Trending Today

Maintenance Pembrolizumab/Olaparib Misses Survival End Points in Locally Advanced or Metastatic TNBC

Pembrolizumab plus olaparib did not improve progression-free or overall survival vs pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer who received induction pembrolizumab plus chemotherapy. ....

San Antonio , United States , Pionyr Immunotherapeutics , Daiichi Sankyo , Sermonix Pharmaceuticals , Novartis Pharmaceuticals , Merck Sharp Dohme , Gilead Sciences , Division Of Hematology , Merck Co Inc , Antonio Breast Cancer , Breast Oncology , Clinical Trials Education , Cancer Care , Merck Sharp , Antonio Breast Cancer Symposium , Helen Diller Family Comprehensive Cancer Center , Hopes Rugo , Breast Cancer , Pembrolizumab Plus Olaparib , Triple Negative Breast Cancer , Phase 2 Keylynk 009 Study , San Antonio Breast Cancer Symposium ,

Keytruda Plus Chemo Improves Complete Response Rate in Breast Cancer

The combination of Keytruda to neoadjuvant chemotherapy, followed by Keytruda in combination with endocrine therapy improved pathologic response rates for patients with early-stage, high-risk, estrogen receptor (ER)–positive/HER2-negative breast cancer. ....

San Antonio , United States , Baylor University , Joyce Oshaughnessy , Breast Cancer Research Program At Texas Oncology , Incorporating Keytruda , Antonio Breast Cancer Symposium , Eastern Europe , Joyceo Shaughnessy , Celebrating Women Chair , Breast Cancer Research , Baylor University Medical Center , Breast Cancer Research Program , Texas Oncology , Within China , Breast Cancer ,

Dr Graff on the Relation Between ctDNA Positivity and Disease Recurrence in HR+/HER2– Breast Cancer

Stephanie L. Graff, MD, discusses findings from a pilot study exploring the association between disease recurrence and circulating tumor DNA positivity in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk, early breast cancer who have received adjuvant treatment of abemaciclib and endocrine therapy.
....

San Antonio , United States , Stephaniel Graff , Breast Cancer Translational Research Disease Group , Warren Alpert Medical School , Lifespan Cancer Institute , Brown University Legorreta Cancer Center , Brown University , Legorreta Cancer Center , Antonio Breast Cancer Symposium , Onclive Tv , Breast Cancer , Endocrine Therapy Interruption , Hr Positive Breast Cancer , Her2 Negative ,

Kisqali Plus Endocrine Therapy Improves Survival in HR+/HER2– Breast Cancer

Patients with HR-positive HER2-negative advanced breast cancer, including elderly patients, derived a progression-free and overall survival benefit with Kisqali plus endocrine therapy compared with placebo plus endocrine therapy. ....

Wake Forest University , North Carolina , United States , Winston Salem , Lowell Hart , Wake Forest University School Of Medicine , Antonio Breast Cancer Symposium , Fort Myers , Wake Forest University School , Breast Cancer , Metastatic Breast Cancer ,

New Capivasertib Approval Benefits Patients With Breast Cancer, PIK3CA/AKT1/PTEN Alterations

Biologic rationale, biomarker precision, and efficacy results in the biomarker-negative population all helped FDA officials decide the final indication. ....

San Antonio , United States , Christy Osgood , Antonio Breast Cancer , Breast Cancer ,